Global Lung Biopsy Systems Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product Type;
Core Needle Biopsy Devices, Fine Needle Aspiration Biopsy Devices, Surgical Biopsy Devices, and Vacuum-Assisted Biopsy Devices.By Procedure Type;
Needle biopsy, Thoracoscopic biopsy, Transbronchial biopsy, and Open biopsy.By End Use;
Hospitals, Cancer Research Centers, Specialty Clinics, Others.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Lung Biopsy Systems Market (USD Million), 2021 - 2031
In the year 2024, the Global Lung Biopsy Systems Market was valued at USD 3,472.13 million. The size of this market is expected to increase to USD 7,772.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.2%.
The global lung biopsy systems market is experiencing a significant surge, driven by a myriad of factors ranging from technological advancements to increasing incidences of respiratory disorders worldwide. Lung biopsy procedures have emerged as crucial diagnostic tools in the assessment of various lung conditions, including cancer, infections, and interstitial lung diseases. As the demand for accurate and minimally invasive diagnostic techniques continues to escalate, the market for lung biopsy systems is witnessing steady growth. One of the key drivers propelling the market expansion is the continuous innovation in biopsy technologies, particularly the development of advanced imaging modalities and biopsy instruments. These innovations not only enhance the precision and efficacy of lung biopsy procedures but also reduce patient discomfort and recovery time.
The rising prevalence of lung cancer and respiratory infections, coupled with the growing aging population, is amplifying the demand for early and accurate diagnosis, thereby fueling the adoption of lung biopsy systems globally. Increasing awareness regarding the importance of timely diagnosis and treatment of respiratory disorders among both healthcare professionals and patients is contributing to market growth.. Despite the promising prospects, challenges such as stringent regulatory guidelines and the high cost associated with advanced biopsy systems pose significant barriers to market penetration, particularly in emerging economies. With ongoing research and development efforts aimed at addressing these challenges, the global lung biopsy systems market is poised for robust expansion in the foreseeable future.
Global Lung Biopsy Systems Market Recent Developments
-
In May 2024, The VERITAS study reveals that Medtronic's fluoroscopic navigation platform provides a safer lung biopsy experience with equivalent diagnostic yield compared to CT-guided biopsies. The trial demonstrates non-inferiority and fewer complications for electromagnetic navigation bronchoscopy in diagnosing lung nodules.
-
In October 2024, Cook County Health celebrated the launch of the Intuitive Surgical ION Navigational Bronchoscopy platform, enhancing lung cancer biopsy procedures. This advanced technology improved diagnosis accuracy and safety, promoting early detection and better outcomes for patients at Stroger Hospital.
Segment Analysis
Core needle biopsy devices, fine needle aspiration biopsy devices, surgical biopsy devices, and vacuum-assisted biopsy devices are essential tools in the diagnosis and staging of various types of cancer. Core needle biopsy devices are commonly used to obtain tissue samples from solid tumors, providing a larger sample for more accurate diagnosis. Fine needle aspiration (FNA) biopsy devices are less invasive, typically used for extracting smaller tissue samples for cytological examination, often for breast, thyroid, or lymph node biopsies. Surgical biopsy devices are used in more invasive procedures when other biopsy methods are insufficient, while vacuum-assisted biopsy devices are designed to collect multiple tissue samples in a single pass, minimizing patient discomfort and improving diagnostic accuracy.
Biopsy procedures play a critical role in diagnosing and staging cancer. Needle biopsy, which includes FNA and core needle biopsies, is the most commonly used method due to its minimally invasive nature. Thoracoscopic biopsy involves using a small camera inserted into the chest to obtain lung tissue samples, while transbronchial biopsy is performed via a bronchoscope to reach deeper parts of the lungs. Open biopsy is a more invasive procedure where a larger incision is made to access and remove tissue for examination, often used when other methods are not sufficient or feasible. Each procedure type is selected based on the location and type of suspected cancer, as well as the patient's overall health.
Hospitals, cancer research centers, specialty clinics, and other healthcare facilities are the primary end-users of these biopsy devices and procedures. Hospitals are equipped with advanced imaging and surgical equipment to perform more complex biopsies and provide comprehensive care. Cancer research centers are often involved in cutting-edge diagnostic and research studies, utilizing these devices to further understand cancer biology and develop new treatments. Specialty clinics offer more focused care, often catering to patients with specific types of cancer or conditions, and may provide both diagnostic and treatment services. Other healthcare settings, such as outpatient centers, also play a role in performing less invasive biopsies, providing timely and cost-effective diagnostic options.
Global Lung Biopsy Systems Segment Analysis
In this report, the Global Lung Biopsy Systems Market has been segmented by Product Type, Procedure Type, End Use, and Geography.
Global Lung Biopsy Systems Market, By Product Type
The Global Lung Biopsy Systems Market has been segmented by Product Type into Core Needle Biopsy Devices, Fine Needle Aspiration Biopsy Devices, Surgical Biopsy Devices and Vacuum-Assisted Biopsy Devices.
Core Needle Biopsy Devices offer precise tissue sampling with minimal invasiveness, making them a preferred choice for diagnosing lung conditions. Their ability to extract tissue cores efficiently aids in accurate pathological examination, crucial for diagnosing malignancies or monitoring disease progression. Fine Needle Aspiration Biopsy Devices provide a less invasive approach, utilizing thin needles to extract cells or fluid for cytological analysis. This method is particularly useful for obtaining samples from hard-to-reach areas or when a less invasive approach is preferred, ensuring patient comfort while enabling effective diagnosis.
Surgical Biopsy Devices represent another vital segment, offering comprehensive tissue samples through surgical intervention. While relatively more invasive, surgical biopsies are essential for complex cases or when larger tissue samples are required for detailed analysis. Lastly, Vacuum-Assisted Biopsy Devices combine the benefits of core needle biopsies with enhanced sample collection using vacuum technology. This segment continues to witness advancements in design and functionality, ensuring efficient tissue retrieval while minimizing patient discomfort. By offering a diverse range of biopsy systems, the market caters to the varying needs of healthcare professionals and patients, driving innovation and improving diagnostic accuracy in lung disease management.
Global Lung Biopsy Systems Market, By Procedure Type
The Global Lung Biopsy Systems Market has been segmented by Procedure Type into Needle biopsy, Thoracoscopic biopsy, Transbronchial biopsy and Open biopsy.
Needle biopsy, a widely utilized technique, offers a minimally invasive approach, allowing for precise tissue sampling with reduced patient discomfort and shorter recovery times. Its popularity stems from its versatility across various lung conditions, including suspected tumors, infections, or interstitial lung diseases. Thoracoscopic biopsy, another prominent method, employs video-assisted thoracoscopic surgery (VATS) to access lung tissue through small incisions, providing real-time visualization and enhancing diagnostic accuracy. This approach is particularly beneficial for lesions located in challenging or inaccessible areas within the lungs, offering clinicians a comprehensive view for informed decision-making.
Transbronchial biopsy represents a valuable tool in the diagnostic armamentarium, facilitated through bronchoscopy, enabling clinicians to obtain lung tissue samples via the bronchial tree. Its non-surgical nature and relative safety make it suitable for patients with compromised lung function or those unfit for invasive procedures. Transbronchial biopsy plays a crucial role in the assessment of pulmonary nodules, lung cancers, and interstitial lung diseases, aiding in the formulation of tailored treatment strategies. Open biopsy, though less common due to its invasive nature, remains indispensable in certain clinical scenarios where extensive tissue sampling or assessment of large lesions is warranted. Despite the availability of less invasive alternatives, open biopsy continues to hold relevance, particularly in cases requiring comprehensive tissue characterization or evaluation of complex pulmonary pathologies.
Global Lung Biopsy Systems Market, By End Use
The Global Lung Biopsy Systems Market has been segmented by End Use into Hospitals, Cancer Research Centers, Specialty Clinics, Others.
Hospitals are the primary setting for advanced diagnostic and treatment procedures, offering comprehensive care for patients requiring biopsies, surgeries, and post-procedural support. They are equipped with the necessary resources, including specialized staff, imaging technology, and surgical facilities, to handle complex cases, particularly for patients with advanced-stage cancers. In hospitals, patients benefit from a multidisciplinary approach, with oncologists, surgeons, radiologists, and other specialists working together to provide the most effective treatment plans, including the use of advanced biopsy techniques to diagnose various forms of cancer.
Cancer research centers focus on advancing the understanding and treatment of cancer. These centers play a crucial role in developing new diagnostic technologies and therapies, often conducting clinical trials and studies to improve cancer care. Biopsy devices and procedures used in these settings are crucial for research purposes, as they help gather tissue samples for molecular analysis and other research applications. These centers also contribute significantly to the development of personalized medicine, where biopsy results help determine the most effective treatments based on the genetic makeup of both the patient and the tumor.
Specialty clinics cater to specific patient needs, often focusing on particular types of cancer or medical conditions. These clinics may specialize in areas like breast cancer, lung cancer, or hematologic disorders, offering diagnostic and treatment services tailored to those conditions. They often serve as more focused environments for patients seeking specialized care, including biopsy procedures, and can provide follow-up care and monitoring for patients undergoing cancer treatment. While specialty clinics might not have the extensive resources of hospitals, they offer targeted care and often work closely with hospitals and research centers for comprehensive treatment plans.
Global Lung Biopsy Systems Market, By Geography
In this report, the Global Lung Biopsy Systems Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Lung Biopsy Systems Market Share (%), by Geographical Region, 2024
In North America, particularly the United States and Canada, the lung biopsy systems market is propelled by robust healthcare infrastructure, significant R&D investments, and a high prevalence of lung diseases. The presence of key market players and a favorable reimbursement scenario further augments market growth in this region. Europe stands as another key market for lung biopsy systems, with countries like Germany, the UK, and France at the forefront. The European market is characterized by increasing adoption of minimally invasive procedures, rising awareness about lung cancer screening, and supportive government initiatives promoting early diagnosis and treatment.
Moving towards the Asia Pacific region, countries such as China, Japan, and India exhibit immense market potential fueled by burgeoning healthcare expenditure, growing geriatric population, and increasing prevalence of respiratory disorders. The market in Asia Pacific is witnessing rapid expansion owing to advancements in healthcare infrastructure, rising disposable incomes, and a shift towards early disease detection and prevention. In the Middle East and Africa, while the market is comparatively nascent, there is a growing emphasis on improving healthcare access, which is expected to drive demand for lung biopsy systems in the region. In Latin America, countries like Brazil and Mexico are witnessing a surge in demand for advanced medical technologies, driven by improving healthcare infrastructure and rising awareness about the benefits of early disease diagnosis and treatment.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Lung Biopsy Systems Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- More lung diseases, like cancer, mean more early treatment
- Better biopsy technology means less invasive procedures
- Aging population leads to more respiratory issues
-
More awareness about early disease detection - With advancements in healthcare education and increasing public health campaigns, there's a noticeable surge in awareness regarding the importance of early disease detection, particularly concerning lung diseases like cancer.
Efforts from healthcare organizations, government initiatives, and non-profit organizations have significantly contributed to educating individuals about the signs and symptoms of lung diseases, emphasizing the benefits of early screening and diagnosis. This heightened awareness encourages individuals to seek medical attention at the earliest signs of respiratory issues, leading to timely interventions, improved treatment outcomes, and potentially saving lives.
Restraints
- Shortage of skilled professionals
- Concerns about safety, especially in older patients
-
Limited resources in rural areas -Despite the progress in healthcare infrastructure, rural areas often face significant challenges due to limited resources, including healthcare facilities, trained medical professionals, and diagnostic equipment. This scarcity poses a barrier to accessing timely and quality healthcare services, including lung disease diagnosis and treatment.
Residents of rural areas may have to travel long distances to reach healthcare facilities capable of performing lung biopsies, leading to delays in diagnosis and treatment initiation. Addressing this issue requires concerted efforts from governments, healthcare organizations, and non-profit entities to improve healthcare accessibility in rural regions through initiatives such as mobile healthcare units, telemedicine services, and training programs for local healthcare providers.
Opportunities
- New biopsy techniques create opportunities
- Partnerships between providers and tech firms expand reach
- AI improves diagnosis
-
Personalized medicine offers new lung cancer treatments - Advancements in medical research and technology have paved the way for personalized medicine approaches in the treatment of lung cancer. These innovative therapies aim to tailor treatment regimens based on individual genetic makeup, tumor characteristics, and other factors, allowing for more precise and effective interventions.
Personalized medicine techniques, such as targeted therapy and immunotherapy, have revolutionized the landscape of lung cancer treatment, offering patients improved survival rates and reduced side effects compared to traditional chemotherapy. With ongoing research and development in this field, personalized medicine continues to unlock new treatment options and therapeutic strategies, heralding a promising era in the fight against lung cancer.
Competitive Landscape Analysis
Key players in Global Lung Biopsy Systems Market include
- Medtronic
- DTR Medical
- B. Braun Melsungen AG
- Argon Medical Devices
- Cardinal Health
- Hologic, Inc.
- Fujifilm Medical Systems
- Olympus Corporation
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Procedure Type
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global Lung Biopsy Systems Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- More lung diseases, like cancer, mean more early treatment
- Better biopsy technology means less invasive procedures
- Aging population leads to more respiratory issues
- More awareness about early disease detection
- Restraints
- Shortage of skilled professionals
- Concerns about safety, especially in older patients
- Limited resources in rural areas
- Opportunities
- New biopsy techniques create opportunities
- Partnerships between providers and tech firms expand reach
- AI improves diagnosis
- Personalized medicine offers new lung cancer treatments
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Lung Biopsy Systems Market, By Product Type, 2021 - 2031 (USD Million)
- Core Needle Biopsy Devices
- Fine Needle Aspiration Biopsy Devices
- Surgical Biopsy Devices
- Vacuum-Assisted Biopsy Devices
- Global Lung Biopsy Systems Market, By Procedure Type, 2021 - 2031 (USD Million)
- Needle biopsy
- Thoracoscopic biopsy
- Transbronchial biopsy
- Open biopsy
- Global Lung Biopsy Systems Market, By End Use, 2021 - 2031 (USD Million)
- Hospitals
- Cancer Research Centers
- Specialty Clinics
- Others
- Global Lung Biopsy Systems Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Lung Biopsy Systems Market, By Product Type, 2021 - 2031 (USD Million)
- Competitive Landscape Analysis
- Company Profiles
- Medtronic
- DTR Medical
- B. Braun Melsungen AG
- Argon Medical Devices
- Cardinal Health
- Hologic, Inc.
- Fujifilm Medical Systems
- Olympus Corporation
- Company Profiles
- Analyst Views
- Future Outlook of the Market